EyePoint Announces Participation at Upcoming Investor Conferences

Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT), a developer of innovative therapeutics for serious retinal diseases, has announced its participation in two major upcoming investor conferences in March 2025.

The company will deliver a corporate presentation at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 4:20 p.m. ET. Additionally, EyePoint will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025, at 3:00 p.m. ET.

Investors can access live webcasts and archived replays of both presentations through the Investors section of EyePoint's website at www.eyepointpharma.com.

News Market Reaction

+6.29%

1 alert

+6.29% News Effect

On the day this news was published, EYPT gained 6.29%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming investor conferences:

• Leerink Partners Global Healthcare Conference
  Forum: Corporate Presentation
  Date: Tuesday, March 11, 2025
  Time: 4:20 p.m. ET

• Barclays 27^th Annual Global Healthcare Conference
  Forum: Fireside Chat
  Date: Wednesday, March 12, 2025
  Time: 3:00 p.m. ET

A live webcast and subsequent archived replay of each presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com.

About EyePoint

EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E^™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU^™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E^™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States and recently completed a Phase 2 clinical trial in diabetic macular edema (DME). Based on positive Phase 2 results from the VERONA clinical trial in DME, EyePoint anticipates meeting with U.S. and ex-U.S. regulatory agencies in the second quarter of 2025 to confirm plans for a pivotal program.

Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E^™ to potentially improve outcomes in serious retinal diseases. The proven Durasert^® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:

Christina Tartaglia
Precision AQ
Direct: 212-698-8700
christina.tartaglia@precisionaq.com

Media Contact:

Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

When is EyePoint Pharmaceuticals (EYPT) presenting at the Leerink Partners Conference in March 2025?

EyePoint will present at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 4:20 p.m. ET.

What type of session will EYPT have at the Barclays Healthcare Conference?

EYPT will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference.

How can investors watch EyePoint's (EYPT) conference presentations?

Investors can access live webcasts and archived replays through the Investors section at www.eyepointpharma.com.

What is the schedule for EYPT's Barclays Conference appearance in March 2025?

EyePoint will participate in the Barclays Conference on Wednesday, March 12, 2025, at 3:00 p.m. ET.